Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability

NCT01957319 is registered in ClinicalTrials.gov with University of Catania as lead sponsor.

NCT NCT01957319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01957319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability
Lead sponsor
University of Catania
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2010
Completion date
July 31, 2013
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, work ability